Response Biomedical Inks Distribution Deal with Fisher HealthCare | GenomeWeb

NEW YORK (GenomeWeb News) – Response Biomedical today said that it has signed a new, nonexclusive deal for Fisher HealthCare to distribute its portfolio of infectious disease tests in the US.

Fisher HealthCare, which is part of Thermo Fisher Scientific, will distribute Response Bio's Infectious Disease Point of Care test panel, which includes the Ramp Flu A + B test and the Ramp RSV test. The assays run on the firm's Ramp 200 system.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.